Bronchopulmonary penetration of isavuconazole in lung transplant recipients

Bronchopulmonary penetration of isavuconazole in lung transplant recipients

Isavuconazole’s (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h resp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrobial agents and chemotherapy 2023-10, Vol.67 (10), p.e0061323-e0061323
Hauptverfasser: Caballero-Bermejo, Antonio F., Darnaude-Ximénez, Ignacio, Aguilar-Pérez, Myriam, Gomez-Lopez, Alicia, Sancho-López, Aránzazu, López García-Gallo, Cristina, Díaz Nuevo, Gema, Diago-Sempere, Elena, Ruiz-Antorán, Belén, Avendaño-Solá, Cristina, Ussetti-Gil, Piedad
Format: Artikel
Sprache:eng
Schlagworte:
Pharmacology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Isavuconazole’s (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h respectively. Mean concentrations in the epithelial lining fluid were 0.969 (SD 0.895), 2.141 (SD 1.265), and 2.812 (SD 0.693) at the same time points. ISA is a drug with a tolerable safety profile that achieves adequate concentrations in the lung.
ISSN:0066-4804
1098-6596
DOI:10.1128/aac.00613-23